Human Epidemiology of Newly Identified Arboviruses

SARS-CoV Infection Clinical Trial

— ARBODOCC  

Official title:

Epidemiology in Humans of New Arbovirusus Sorted Out From Metagenomic Screen in Local Vectors and Animal Hosts.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04954352
• Other study ID #: RECHMPL21_0297
• Status: Recruiting
• Start date: January 1, 2020
• Est. completion date: December 30, 2024

Study information

• Verified date: July 2021
• Source: University Hospital, Montpellier
• Contact: Yannick Simonin, PhD
• Phone: 434359114
• Email: yannick.simonin[@]umontpellier.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A local network is being set up to study the impact of arboviruses in our region. It is committed to a one-health approach, in particular with research without a priori for new viruses hosted among vectors and wildlife. The candidates identified by high throughput sequencing approaches will serve as a basis for the development of serological and molecular tools for their detections. These tools will be used to assess the possible circulation of these new viruses in humans in biological collections created within the framework of this project Arbodocc .

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: December 30, 2024
• Est. primary completion date: December 20, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 80 Years

Eligibility

Inclusion criteria:

• Patients admitted at the Monpellier University Hospital for any infectious syndrome compatible with an arboviral infection with samples available

Exclusion criteria:

• Informed consent non obtain for samples used

Related Conditions & MeSH terms

• Arbovirus Infections
• Communicable Diseases
• Infection
• SARS-CoV Infection
• Severe Acute Respiratory Syndrome

Locations

Country	Name	City	State
France	Uh Montpellier	Montpellier

Sponsors (4)

Lead Sponsor	Collaborator
University Hospital, Montpellier	Institut Pasteur, UMR ASTRE (CIRAD), UMR PCCEI

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seroprevalence	Detection of antibodies targeting specific antigens of newly identified arboviruses	1 day
Secondary	Molecular detection	Detection of newly identified arboviruses genome	1 day